EP2563121A4 - METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC AGENTS - Google Patents
METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC AGENTSInfo
- Publication number
- EP2563121A4 EP2563121A4 EP11775615.5A EP11775615A EP2563121A4 EP 2563121 A4 EP2563121 A4 EP 2563121A4 EP 11775615 A EP11775615 A EP 11775615A EP 2563121 A4 EP2563121 A4 EP 2563121A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- protecting against
- neurotoxic agents
- against neurotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/771,476 US20100310609A1 (en) | 2007-10-25 | 2010-04-30 | Compositions and methods for treatment of neurodegenerative diseases |
US41389910P | 2010-11-15 | 2010-11-15 | |
US201161454409P | 2011-03-18 | 2011-03-18 | |
PCT/US2011/034508 WO2011137317A1 (en) | 2010-04-30 | 2011-04-29 | Methods and compositions for protecting against neurotoxic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2563121A1 EP2563121A1 (en) | 2013-03-06 |
EP2563121A4 true EP2563121A4 (en) | 2016-05-11 |
Family
ID=44861925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11775615.5A Withdrawn EP2563121A4 (en) | 2010-04-30 | 2011-04-29 | METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC AGENTS |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2563121A4 (ja) |
JP (1) | JP5941908B2 (ja) |
KR (1) | KR20130113314A (ja) |
CN (1) | CN103002734A (ja) |
AU (1) | AU2011245223B2 (ja) |
BR (1) | BR112012027905A2 (ja) |
CA (1) | CA2798127A1 (ja) |
EA (1) | EA201201483A1 (ja) |
IL (1) | IL222757A0 (ja) |
MX (1) | MX2012012634A (ja) |
WO (1) | WO2011137317A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
BR112013003110A2 (pt) * | 2010-08-12 | 2016-06-28 | Revalesio Corp | composições e métodos para tratamento de taupatia |
JP6159584B2 (ja) * | 2012-06-14 | 2017-07-05 | 松本 高明 | 輸液、輸液の製造方法および輸液装置 |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
US20180243247A1 (en) * | 2017-02-28 | 2018-08-30 | Bryan J. Katz | Drug combinations for cerebrovascular disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05010042A (es) * | 2003-03-20 | 2006-05-25 | Aquaphotonics Inc | Composiciones de farmacos en micro-agregados, composiciones bioafectadoras, composiciones para el tratamiento corporal, medios de cultivo, alimentos y bebidas. |
ITMI20061737A1 (it) * | 2006-09-12 | 2008-03-13 | Snam Progetti | Procedimento per il trasporto di zolfo a basso rischio e ad emissione zero da depositi di zolfo solido in blocchi di notevoli dimensioni |
US20100310609A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Compositions and methods for treatment of neurodegenerative diseases |
US9745567B2 (en) * | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
WO2009134728A2 (en) * | 2008-04-28 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
-
2011
- 2011-04-29 MX MX2012012634A patent/MX2012012634A/es not_active Application Discontinuation
- 2011-04-29 CA CA2798127A patent/CA2798127A1/en not_active Abandoned
- 2011-04-29 BR BR112012027905A patent/BR112012027905A2/pt not_active IP Right Cessation
- 2011-04-29 JP JP2013508277A patent/JP5941908B2/ja not_active Expired - Fee Related
- 2011-04-29 WO PCT/US2011/034508 patent/WO2011137317A1/en active Application Filing
- 2011-04-29 KR KR1020127031216A patent/KR20130113314A/ko not_active Application Discontinuation
- 2011-04-29 EP EP11775615.5A patent/EP2563121A4/en not_active Withdrawn
- 2011-04-29 CN CN2011800318038A patent/CN103002734A/zh active Pending
- 2011-04-29 AU AU2011245223A patent/AU2011245223B2/en not_active Ceased
- 2011-04-29 EA EA201201483A patent/EA201201483A1/ru unknown
-
2012
- 2012-10-29 IL IL222757A patent/IL222757A0/en unknown
Non-Patent Citations (5)
Title |
---|
ASHUTOSH AGARWAL ET AL: "Principle and applications of microbubble and nanobubble technology for water treatment", CHEMOSPHERE., vol. 84, no. 9, 1 August 2011 (2011-08-01), GB, pages 1175 - 1180, XP055234995, ISSN: 0045-6535, DOI: 10.1016/j.chemosphere.2011.05.054 * |
CHAPLIN MARTIN: "Nanobubbles (ultrafine bubbles)", 6 November 2015 (2015-11-06), pages 1 - 12, XP055235029, Retrieved from the Internet <URL:http://www1.lsbu.ac.uk/water/nanobubble.html> [retrieved on 20151209] * |
LEE ET AL: "Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity", TOXICOLOGY, LIMERICK, IR, vol. 243, no. 1-2, 14 December 2007 (2007-12-14), pages 43 - 50, XP022391166, ISSN: 0300-483X * |
See also references of WO2011137317A1 * |
USHIKUBO F Y ET AL: "Evidence of the existence and the stability of nano-bubbles in water", COLLOIDS AND SURFACES. A, PHYSICACHEMICAL AND ENGINEERING ASPECTS, ELSEVIER, AMSTERDAM, NL, vol. 361, no. 1-3, 20 May 2010 (2010-05-20), pages 31 - 37, XP027030201, ISSN: 0927-7757, [retrieved on 20100311] * |
Also Published As
Publication number | Publication date |
---|---|
JP5941908B2 (ja) | 2016-06-29 |
IL222757A0 (en) | 2012-12-31 |
KR20130113314A (ko) | 2013-10-15 |
CN103002734A (zh) | 2013-03-27 |
CA2798127A1 (en) | 2011-11-03 |
EA201201483A1 (ru) | 2013-04-30 |
BR112012027905A2 (pt) | 2015-09-08 |
EP2563121A1 (en) | 2013-03-06 |
MX2012012634A (es) | 2013-02-26 |
AU2011245223B2 (en) | 2015-11-19 |
AU2011245223A1 (en) | 2013-01-10 |
JP2013529195A (ja) | 2013-07-18 |
WO2011137317A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263729A (en) | Preparations and methods for removing biofilms | |
HK1246715A1 (zh) | 用於靶向熱調節的組合物和方法 | |
GB201014618D0 (en) | Respirtory protection equipment | |
ZA201209259B (en) | Uses and compositions | |
EP2552953A4 (en) | FRIZZLED-BINDING SUBSTANCES AND ITS USES | |
ZA201208948B (en) | Modified beta-lactamases and methods and uses related thereto | |
EP2629742A4 (en) | HAIR CARE COMPOSITIONS AND RELATED METHODS | |
EP2575825A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | |
GB201113485D0 (en) | Corrosion protection | |
PL2501847T3 (pl) | Rękawica ochronna | |
EP2533645A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | |
EP2563121A4 (en) | METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC AGENTS | |
EP2601269A4 (en) | ANTI-ABSORPTION COMPOSITIONS AND METHOD FOR THEIR USE | |
EP2609160A4 (en) | COATING COMPOSITION | |
EP2632460A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TUBERCULOSIS | |
HK1167522A1 (zh) | 保護裝置 | |
HK1201451A1 (en) | Compositions and methods | |
GB201018650D0 (en) | Methods and compositions | |
EP2931280A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1 | |
HK1254904B (zh) | 用於改變xlhed表型的組合物和方法 | |
HK1170854A1 (zh) | 用於保護免受電流浪涌影響的設備的組合 | |
HK1167521A1 (zh) | 保護裝置 | |
EP2686335A4 (en) | DECORINAL COMPOSITIONS AND THEIR USE | |
HK1167350A1 (en) | Methods and compositions for protecting and treating neuroinjury | |
EP2603610A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING A LUPUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121129 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160407 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20170317 |